Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 15Neoplasm Metastasis 5Colonic Neoplasms 2Sarcoma 1Rectal Neoplasms 1Neoplasms 1Metastatic Pancreatic Ductal Adenocarcinoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

venetoclax 1itacitinib 1drozitumab 1birinapant 1baricitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Leucovorin 1Irinotecan 1Ifosfamide 1INCB039110 1IFL protocol 1Gemcitabine 1Fluorouracil 1Docetaxel 1Cyproheptadine 1Cyclophosphamide 1Cryosurgery 1Bevacizumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Chondrosarcoma × IFL protocol × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡